Targeting Subcellular Organelles in Breast Cancer with Enzyme Induced Self-Assembly: Stimulated Response with

Emily Carney1, Robert Powell1, Ananya Kumar1

  • 1Department of Biomedical Engineering, University of North Texas, Denton, Texas 76207, United States.

Molecular Pharmaceutics
|September 15, 2025
PubMed

Insights

Enzyme-induced peptide self-assembly overcomes cancer drug resistance. Fmoc-FF-pTyr peptides trigger cancer cell apoptosis and DNA damage, while Nap-containing peptides enhance chemotherapy, offering new nanotherapeutic strategies.

Area of Science:

  • Biochemistry
  • Nanotechnology
  • Oncology

Background:

  • Enzyme-induced peptide self-assembly is a promising strategy to overcome cancer drug resistance.
  • Optimal precursor design and understanding subcellular interactions are crucial for targeted cancer therapy.

Purpose of the Study:

  • To synthesize and evaluate short peptides for enzyme-induced self-assembly and cancer cell targeting.
  • To investigate the subcellular interactions and therapeutic potential of novel peptide precursors in breast cancer models.

Main Methods:

  • Synthesis of six modified short peptides (Fmoc, FF, RGD, Nap, NBD, pTyr, pThr).
  • Utilized Eye Absent Enzyme (EYA) tyrosine phosphatase activity to induce peptide self-assembly in breast cancer cells (MDA-MB-231, MCF-7, MCF10).
  • Evaluated subcellular localization (DNA, mitochondria, cell membrane) and binding affinity (phosphatidylserine).

Main Results:

  • EYA dephosphorylation induced peptide self-assembly, confirmed by UV shift and phosphate release.
  • Peptide assemblies localized to the cell membrane, entered cells, and accumulated in nuclei.
  • Fmoc-FF-pTyr induced DNA damage and apoptosis in cancer cells, with minimal toxicity to normal cells.
  • Nap-containing peptides accumulated in mitochondria, enhancing doxorubicin efficacy.

Conclusions:

  • EYA-mediated self-assembly of peptide precursors offers a novel pathway for breast cancer therapy.
  • Peptide precursor design is critical for modulating phosphatase-induced pathways and achieving targeted nanotherapeutics.
  • Fmoc-FF-pTyr and Nap-containing peptides show significant potential for cancer treatment and combination therapy.